Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Cancer Drug Interactions Revealed

July 9, 2007 | A version of this story appeared in Volume 85, Issue 28

The detailed manner by which the cancer drug etoposide interacts with its enzyme target, topoisomerase II, has been revealed for the first time. Etoposide, the most widely prescribed anticancer drug in the world until the development of paclitaxel, is in its third decade of approved clinical use to treat a variety of cancers, including leukemias, lymphomas, and solid tumors. But the interactions of the drug with topoisomerase II had never been identified, until now. Neil Osheroff of Vanderbilt University School of Medicine; David E. Graves of the University of Alabama, Birmingham; and coworkers used saturation transfer difference NMR spectroscopy to identify the points of contact and their functional significance (Biochemistry, DOI: 10.1021/bi700272u). They find that three of etoposide's five rings interact with the enzyme, while the other two rings and the drug's glycosidic moiety do not. The study has "predictive value that may contribute to the future development of etoposide derivatives with greater activity against topoisomerase II," the researchers write.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.